The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...

PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

PYX-201 is a first-in-concept antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix ...

(RTTNews) - Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the ...

Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...

PYX-201 is a first-in-concept antibody-drug conjugate (ADC) targeting Extradomain-B Fibronectin (EDB+FN), a component within the tumor extracellular matrix, which is highly expressed in various ...

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from ...